Navigation Links
Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
Date:8/25/2008

component of our international cardiovascular development program. The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"Based upon the success of varespladib in two previous Phase II clinical trials in patients with cardiovascular disease in which it demonstrated lipid-lowering and anti-inflammatory benefits, we look forward to further evaluating the impact of varespladib on the hyper-inflammatory state presented by ACS patients," said Dr. James Pennington, Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acq
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 7, 2011 CareFusion Corporation (NYSE: ... today the appointment of Carlos M. Nunez, M.D. as its ... an anesthesiologist, intensivist and hospitalist as well as an experienced ... business career in the areas of clinical effectiveness, information technology, ...
... CHICAGO, March 7, 2011 General Nutrition Company (GNC) ... products manufacturer Sakar International for a line of more ... line,s initial merchandise offerings will range from heart rate ... and electronic pill boxes. The products ...
Cached Medicine Technology:CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 3
(Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... was the first in the world to discover a ... the jaw. , Ameloblastoma is an odontogenic tumour with ... most often found in the posterior of the lower ... tissue deficiencies in the jaws as well as loss ... the need for surgery and the recurrence of ameloblastoma, ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... General Hospital (MGH) investigators may lead to greater availability ... medical problem use of fecal material from healthy ... Clostridium difficile ( C. difficile ) bacteria. ... Clinical Infectious Diseases , the researchers report that ... to patients was as successful in curing recurrent ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... This release is available in German . ... and learning about the warning signs of lymphedema: that,s ... lymphedema, according to the German Institute for Quality and ... about how to protect themselves from this common and ...
... AUGUSTA, Maine, Nov. 6 Building on the ... for small businesses in Maine,the Maine State Chamber ... and Blue Shield have announced further additions to ... January, Chamber,BlueOptions will include eight health plans from ...
... Invisicare Is Put In Place, LAS VEGAS, ... the developers of Invisicare, a patented polymer,delivery system ... of Geert Cauwenbergh, PhD to head its International,Advisory ... expand the demand,for Invisicare in international markets. Dr. ...
... Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (Amex: ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... to discuss its,2009 fiscal first quarter at 8:30 ... will be released that day before the market ...
... A steady march toward using,ever-more "patient-friendly" ... proceedings of the 37th Global Congress of ... international professional society for,specialists in minimally invasive ... preserving the highest possible quality of,life for ...
... People With,Diabetes and Their Caregivers, WESTPORT, Conn., Nov. ... laughter, and family, usually accompanied by trays of cookies,cakes, ... some,of the nearly 24 million people in America with ... dLife helped over 100,000 online,visitors survive the season with ...
Cached Medicine News:Health News:How women can improve their quality of life after breast cancer treatment 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 3Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 4Health News:Back By Popular Demand - dLife Holiday Helpline 2
... System 9700 can now be used with ... The aluminum block has been designed for ... sequencing in a conventional 8 X 12 ... system to be used in 9600 emulation ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... for day-to-day temperature cycling ... 0.1C ,30% reduction in ... or coolant-based cyclers ,4 ... ramping ,Options for oil-free ...
... TC-512 has a graphical touch screen display ... at the "touch of a screen." ... gradient, Touch Screen, Graphical Display, Memory Cards, ... Block Format, Intuitive Programmin, Free Instrument Software ...
Medicine Products: